Results 31 to 40 of about 509,494 (205)

High-Resolution Genome-Wide Single Nucleotide Polymorphism Mapping in Acute Myeloid Leukaemia [PDF]

, 2008
PhDInvestigation of the genetics of acute myeloid leukaemia (AML) has revealed the underlying basis of the disease and led to targets for therapy. High-resolution single nucleotide polymorphism (SNP) arrays detected regions of loss of heterozygosity ...
Raghavan, Manoj
core   +4 more sources

Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia

Haematologica, 2012
The recent identification of DNMT3A mutations in de novo acute myeloid leukemia prompted us to determine their frequency, patterns and clinical impact in a cohort of 98 patients with either therapy-related or secondary acute myeloid leukemia developing ...
Isabella Fried, Claudia Bodner, Monika M. Pichler, Karin Lind, Christine Beham-Schmid, Franz Quehenberger, Wolfgang R. Sperr, Werner Linkesch, Heinz Sill, Albert Wölfler   +9 more
doaj   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T., Tessa Holyoake, Michor Franziska, Michor, F., Holyoake Tessa, Clarkson Bayard, Foo, J., Mark W Drummond, Franziska Michor, Bayard Clarkson, Foo Jasmine, Drummond, M.W., Jasmine Foo, Clarkson, B., Drummond Mark W.   +14 more
core   +2 more sources

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters [PDF]

, 2009
Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34⁺ cells.
Holyoake, T.L., Davies, A., Jordanides, N.E., Giannoudis, A., Jorgensen, H.G., Harris, R.J., Hatziieremia, S., Mountford, J.C., Pirmohamed, M., Clark, R.E., Lucas, C.M.   +10 more
core   +2 more sources

Acute Myeloid Leukemia

Apollo Medicine, 2004
AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone, Margaret R, O'Donnell, Mikkael A, Sekeres   +2 more
openaire   +3 more sources

Signaling through CD44 affects cell cycle progression and c-Jun expression in acute myeloid leukemia cells [PDF]

, 2004
We present here the first evidence linking CD44 signaling to c-Jun expression and cell cycle progression in myeloid cell line models. CD44 ligation with the anti-CD44 monoclonal antibodies have been shown to induce differentiation and inhibit the ...
Peer Zada, Abdul Ali
core   +1 more source

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations

Haematologica, 2014
Somatic mutations of TET2, IDH1, and IDH2 have been described in myelodysplastic syndrome. The impact of these mutations on outcome of myelodysplastic syndrome and their progression to secondary acute myeloid leukemia remains unclear.
Tung-Liang Lin, Yasunobu Nagata, Hsiao-Wen Kao, Masashi Sanada, Yusuke Okuno, Chein-Fuang Huang, Der-Cherng Liang, Ming-Chung Kuo, Chang-Liang Lai, En-Hui Lee, Yu-Shu Shih, Hiroko Tanaka, Yuichi Shiraishi, Kenichi Chiba, Tung-Huei Lin, Jin-Hou Wu, Satoru Miyano, Seishi Ogawa, Lee-Yung Shih   +18 more
doaj   +1 more source

Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells

Haematologica, 2018
Acute myeloid leukemia is a disorder characterized by abnormal differentiation of myeloid cells and a clonal proliferation derived from primitive hematopoietic stem cells.
Dang Wu, Wanyan Wang, Wuyan Chen, Fulin Lian, Li Lang, Ying Huang, Yechun Xu, Naixia Zhang, Yinbin Chen, Mingyao Liu, Ruth Nussinov, Feixiong Cheng, Weiqiang Lu, Jin Huang   +13 more
doaj   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Hatziieremia, S., Mountford, J.C.   +4 more
core   +1 more source

t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients

Haematologica, 2014
Acute myeloid leukemia with t(6;9)(p22;q34) is listed as a distinct entity in the 2008 World Health Organization classification, but little is known about the clinical implications of t(6;9)-positive myeloid leukemia in children.
Julie Damgaard Sandahl, Eva A. Coenen, Erik Forestier, Jochen Harbott, Bertil Johansson, Gitte Kerndrup, Souichi Adachi, Anne Auvrignon, H. Berna Beverloo, Jean-Michel Cayuela, Lucy Chilton, Maarten Fornerod, Valérie de Haas, Christine J. Harrison, Hiroto Inaba, Gertjan J.L. Kaspers, Der-Cherng Liang, Franco Locatelli, Riccardo Masetti, Christine Perot, Susana C. Raimondi, Katarina Reinhardt, Daisuke Tomizawa, Nils von Neuhoff, Marco Zecca, C. Michel Zwaan, Marry M. van den Heuvel-Eibrink, Henrik Hasle   +27 more
doaj   +1 more source